Tacrolimus is an alternative therapeutic option for the treatment of refractory lupus nephritis
| Autor: | Ho Jun Chin, Kwon-Wook Joo, Han Js, Curie Ahn, Keunhee Oh, Yon Su Kim, Lee T, Sun-Whe Kim |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Adult
Male medicine.medical_specialty Cyclophosphamide Urinary system Urology Lupus nephritis Tacrolimus Rheumatology Refractory medicine Humans Prospective Studies Treatment Failure Adverse effect Proteinuria business.industry Middle Aged medicine.disease Lupus Nephritis Regimen Treatment Outcome Immunology Disease Progression Female medicine.symptom business Immunosuppressive Agents medicine.drug |
| Zdroj: | Lupus. 19:974-980 |
| ISSN: | 1477-0962 0961-2033 |
| Popis: | We conducted an open-labeled, prospective study to determine the efficacy and safety of tacrolimus as an alternative therapeutic option for those patients with refractory lupus nephritis. The study population comprised one male and eight female patients with diffuse proliferative lupus nephritis. All patients had failed to respond to sufficient intravenous cyclophosphamide therapy with proteinuria of ≥1 g/day and active urinary sediments. Tacrolimus (0.1 mg/kg/day) was administered for 1 year with adjusting drug level (4—10 µg/l). The mean serum creatinine level and spot urine protein creatinine ratio (UPCR) at baseline were 1.39 mg/dl and 2.27, respectively. After the treatment, proteinuria reduced significantly from median UPCR value of 2.19 (range, 1.19—3.34) to 0.44 (range, 0.12—2.13) (p < 0.05). Seven (78%) of the nine patients showed a complete clinical response, which was defined as stabilization in the disease-activity markers and serum creatinine level with reduction of ≥50% in UPCR; two patients showed complete remission with UPCR |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|